{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:05:32Z","timestamp":1783465532043,"version":"3.55.0"},"reference-count":64,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Splicing defects caused by mutations in the consensus sequences at the borders of introns and exons are common in human diseases. Such defects frequently result in a complete loss of function of the protein in question. Therapy approaches based on antisense oligonucleotides for specific gene mutations have been developed in the past, but they are very expensive and require invasive, life-long administration. Thus, modulation of splicing by means of small molecules is of great interest for the therapy of genetic diseases resulting from splice-site mutations. Using minigene approaches and patient cells, we here show that methylxanthine derivatives and the food-derived flavonoid luteolin are able to enhance the correct splicing of the AGA mRNA with a splice-site mutation c.128-2A&gt;G in aspartylglucosaminuria, and result in increased AGA enzyme activity in patient cells. Furthermore, we also show that one of the most common disease causing TPP1 gene variants in classic late infantile neuronal ceroid lipofuscinosis may also be amenable to splicing modulation using similar substances. Therefore, our data suggest that splice-modulation with small molecules may be a valid therapy option for lysosomal storage disorders.<\/jats:p>","DOI":"10.3390\/cells10112813","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T21:29:46Z","timestamp":1634765386000},"page":"2813","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Towards Splicing Therapy for Lysosomal Storage Disorders: Methylxanthines and Luteolin Ameliorate Splicing Defects in Aspartylglucosaminuria and Classic Late Infantile Neuronal Ceroid Lipofuscinosis"],"prefix":"10.3390","volume":"10","author":[{"given":"Antje","family":"Banning","sequence":"first","affiliation":[{"name":"Institute of Biochemistry, Medical Faculty, University of Giessen, Friedrichstrasse 24, 35392 Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8393-1825","authenticated-orcid":false,"given":"Ritva","family":"Tikkanen","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry, Medical Faculty, University of Giessen, Friedrichstrasse 24, 35392 Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13023-016-0544-6","article-title":"Aspartylglycosaminuria: A review","volume":"11","author":"Arvio","year":"2016","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/0883073820980904","article-title":"Aspartylglucosaminuria: Clinical Presentation and Potential Therapies","volume":"36","author":"Goodspeed","year":"2021","journal-title":"J. Child Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/hmg\/10.9.983","article-title":"Molecular pathogenesis of a disease: Structural consequences of aspartylglucosaminuria mutations","volume":"10","author":"Saarela","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"37583","DOI":"10.1038\/srep37583","article-title":"Identification of Small Molecule Compounds for Pharmacological Chaperone Therapy of Aspartylglucosaminuria","volume":"6","author":"Banning","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_5","unstructured":"(2020, October 09). EU Clinical Trials Register. Available online: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-000645-48\/FI."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.bbadis.2017.12.014","article-title":"Amlexanox provides a potential therapy for nonsense mutations in the lysosomal storage disorder Aspartylglucosaminuria","volume":"1864","author":"Banning","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.ymthe.2020.11.012","article-title":"Pre-clinical Gene Therapy with AAV9\/AGA in Aspartylglucosaminuria Mice Provides Evidence for Clinical Translation","volume":"29","author":"Chen","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_8","unstructured":"(2020, September 29). Human Gene Mutation Database. Available online: http:\/\/www.hgmd.cf.ac.uk\/ac\/index.php."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/embor.2009.170","article-title":"Missed threads. The impact of pre-mRNA splicing defects on clinical practice","volume":"10","author":"Baralle","year":"2009","journal-title":"EMBO Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"Fokkema","year":"2009","journal-title":"Hum. Mutat."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","article-title":"Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study","volume":"378","author":"Cirak","year":"2011","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1011367","article-title":"Systemic administration of PRO051 in Duchenne\u2019s muscular dystrophy","volume":"364","author":"Goemans","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1056\/NEJMoa073108","article-title":"Local dystrophin restoration with antisense oligonucleotide PRO051","volume":"357","author":"Janson","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/nrneurol.2016.199","article-title":"Motor neuron disease: Nusinersen potentially effective in SMA","volume":"13","author":"Adams","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"72ra18","DOI":"10.1126\/scitranslmed.3001777","article-title":"Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy","volume":"3","author":"Passini","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/s41591-020-0986-1","article-title":"Therapeutic efficacy of antisense oligonucleotides in mouse models of CLN3 Batten disease","volume":"26","author":"Centa","year":"2020","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease","volume":"381","author":"Kim","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in Type 1 Spinal Muscular Atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","article-title":"Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 (SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)","volume":"61","author":"Ratni","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"17472","DOI":"10.1038\/s41598-020-74346-9","article-title":"Discovery of a CNS penetrant small molecule SMN2 splicing modulator with improved tolerability for spinal muscular atrophy","volume":"10","author":"Ando","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nchembio.1837","article-title":"SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice","volume":"11","author":"Palacino","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/acn3.51239","article-title":"Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy","volume":"8","author":"Sergott","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Kapahnke, M., Banning, A., and Tikkanen, R. (2016). Random Splicing of Several Exons Caused by a Single Base Change in the Target Exon of CRISPR\/Cas9 Mediated Gene Knockout. Cells, 5.","DOI":"10.3390\/cells5040045"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Fujita, K.I., Ishizuka, T., Mitsukawa, M., Kurata, M., and Masuda, S. (2020). Regulating Divergent Transcriptomes through mRNA Splicing and Its Modulation Using Various Small Compounds. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21062026"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Keeling, K.M., Wang, D., Dai, Y., Murugesan, S., Chenna, B., Clark, J., Belakhov, V., Kandasamy, J., Velu, S.E., and Baasov, T. (2013). Attenuation of nonsense-mediated mRNA decay enhances in vivo nonsense suppression. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060478"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/cbdd.12656","article-title":"A Splicing Reporter Tuned to Non-AG Acceptor Sites Reveals that Luteolin Enhances the Recognition of Non-canonical Acceptor Sites","volume":"87","author":"Chiba","year":"2016","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00109-006-0137-2","article-title":"Therapeutic potential and mechanism of kinetin as a treatment for the human splicing disease familial dysautonomia","volume":"85","author":"Hims","year":"2007","journal-title":"J. Mol. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/hmg\/ddh046","article-title":"Rescue of a human mRNA splicing defect by the plant cytokinin kinetin","volume":"13","author":"Slaugenhaupt","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1574-6968.2001.tb10897.x","article-title":"A fluorescence quenching test for the detection of flavonoid transformation","volume":"204","author":"Schoefer","year":"2001","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1089\/dna.1995.14.305","article-title":"Intracellular sorting of aspartylglucosaminidase: The role of N-linked oligosaccharides and evidence of Man-6-P-independent lysosomal targeting","volume":"14","author":"Tikkanen","year":"1995","journal-title":"DNA Cell Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/humu.23860","article-title":"Mutation update: Review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease","volume":"40","author":"Gardner","year":"2019","journal-title":"Hum. Mutat."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/wrna.1260","article-title":"The RNAissance family: SR proteins as multifaceted regulators of gene expression","volume":"6","author":"Howard","year":"2015","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14348\/molcells.2017.2319","article-title":"SR Proteins: Binders, Regulators, and Connectors of RNA","volume":"40","author":"Jeong","year":"2017","journal-title":"Mol. Cells"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.biocel.2013.12.004","article-title":"Caffeine induces tumor cytotoxicity via the regulation of alternative splicing in subsets of cancer-associated genes","volume":"47","author":"Lu","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1128\/MCB.01345-07","article-title":"Caffeine regulates alternative splicing in a subset of cancer-associated genes: A role for SC35","volume":"28","author":"Shi","year":"2008","journal-title":"Mol. Cell Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"14986","DOI":"10.1074\/jbc.M114.624254","article-title":"Methylxanthines Increase Expression of the Splicing Factor SRSF2 by Regulating Multiple Post-transcriptional Mechanisms","volume":"290","author":"Shi","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.isci.2019.11.033","article-title":"Food-Derived Compounds Apigenin and Luteolin Modulate mRNA Splicing of Introns with Weak Splice Sites","volume":"22","author":"Kurata","year":"2019","journal-title":"iScience"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Kitamura, K., and Nimura, K. (2021). Regulation of RNA Splicing: Aberrant Splicing Regulation and Therapeutic Targets in Cancer. Cells, 10.","DOI":"10.3390\/cells10040923"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev-biochem-060614-034316","article-title":"Mechanisms and Regulation of Alternative Pre-mRNA Splicing","volume":"84","author":"Lee","year":"2015","journal-title":"Annu. Rev. Biochem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.canlet.2006.03.032","article-title":"The enigmatic effects of caffeine in cell cycle and cancer","volume":"247","author":"Bode","year":"2007","journal-title":"Cancer Lett."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1101\/gad.913001","article-title":"Human SMG-1, a novel phosphatidylinositol 3-kinase-related protein kinase, associates with components of the mRNA surveillance complex and is involved in the regulation of nonsense-mediated mRNA decay","volume":"15","author":"Yamashita","year":"2001","journal-title":"Genes Dev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.bbrc.2018.05.193","article-title":"Readthrough of ACTN3 577X nonsense mutation produces full-length alpha-actinin-3 protein","volume":"502","author":"Harada","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e01963","DOI":"10.1016\/j.heliyon.2019.e01963","article-title":"Caffeine boosts Ataluren\u2019s readthrough activity","volume":"5","author":"Lentini","year":"2019","journal-title":"Heliyon"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/cns.12684","article-title":"The neuroprotective effects of caffeine in neurodegenerative diseases","volume":"23","author":"Kolahdouzan","year":"2017","journal-title":"CNS Neurosci. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.2147\/COPD.S150887","article-title":"Doxofylline is not just another theophylline!","volume":"12","author":"Matera","year":"2017","journal-title":"Int. J. Chron. Obstr. Pulmon. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1164\/rccm.201302-0388PP","article-title":"Theophylline","volume":"188","author":"Barnes","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"101461","DOI":"10.18632\/oncotarget.21464","article-title":"Theophylline exhibits anti-cancer activity via suppressing SRSF3 in cervical and breast cancer cell lines","volume":"8","author":"Chang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"8921","DOI":"10.1073\/pnas.132556899","article-title":"A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression","volume":"99","author":"Ito","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1164\/rccm.200210-1142PP","article-title":"Theophylline: New perspectives for an old drug","volume":"167","author":"Barnes","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_50","unstructured":"Annamaraju, P., and Baradhi, K.M. (2020). Pentoxifylline, StatPearls."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1097\/HJH.0000000000001086","article-title":"Effects of pentoxifylline on inflammatory markers and blood pressure: A systematic review and meta-analysis of randomized controlled trials","volume":"34","author":"Brie","year":"2016","journal-title":"J. Hypertens."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/2472555218792264","article-title":"Development of a Screening Platform to Identify Small Molecules That Modify ELP1 Pre-mRNA Splicing in Familial Dysautonomia","volume":"24","author":"Salani","year":"2019","journal-title":"SLAS Discov."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1203\/PDR.0b013e31822e1825","article-title":"Kinetin improves IKBKAP mRNA splicing in patients with familial dysautonomia","volume":"70","author":"Axelrod","year":"2011","journal-title":"Pediatr. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"E2153","DOI":"10.1073\/pnas.1303726110","article-title":"Molecular basis for the action of a dietary flavonoid revealed by the comprehensive identification of apigenin human targets","volume":"110","author":"Arango","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainresbull.2015.09.002","article-title":"Luteolin as an anti-inflammatory and neuroprotective agent: A brief review","volume":"119","author":"Nabavi","year":"2015","journal-title":"Brain Res. Bull."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3892\/mmr.2017.6582","article-title":"Luteolin-induced apoptosis through activation of endoplasmic reticulum stress sensors in pheochromocytoma cells","volume":"16","author":"Kwon","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"109084","DOI":"10.1016\/j.biopha.2019.109084","article-title":"Corrigendum to \u201cLuteolin, a flavonoid, as an anticancer agent: A review\u201d [Biomed. Pharmacother. 112 (2019) 108612]","volume":"116","author":"Imran","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_58","first-page":"1","article-title":"Luteolin promotes apoptotic cell death via upregulation of Nrf2 expression by DNA demethylase and the interaction of Nrf2 with p53 in human colon cancer cells","volume":"51","author":"Kang","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/138955709787001712","article-title":"Distribution and biological activities of the flavonoid luteolin","volume":"9","year":"2009","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1002\/ijc.22790","article-title":"A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer","volume":"121","author":"Gates","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.numecd.2005.01.001","article-title":"Dietary and serum vitamins and minerals as predictors of myocardial infarction and stroke in elderly subjects","volume":"15","author":"Marniemi","year":"2005","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.clinthera.2013.04.006","article-title":"An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders","volume":"35","author":"Taliou","year":"2013","journal-title":"Clin. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/039463201202500201","article-title":"A case series of a luteolin formulation (NeuroProtek(R)) in children with autism spectrum disorders","volume":"25","author":"Theoharides","year":"2012","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.bbr.2007.12.010","article-title":"Assessment of luteolin (3\u2032,4\u2032,5,7-tetrahydroxyflavone) neuropharmacological activity","volume":"189","author":"Coleta","year":"2008","journal-title":"Behav. Brain Res."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/11\/2813\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:19:16Z","timestamp":1760167156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/11\/2813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,20]]},"references-count":64,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["cells10112813"],"URL":"https:\/\/doi.org\/10.3390\/cells10112813","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,20]]}}}